Akari Therapeutics AKTX 深 滬
交易中 09-25 11:38:08 美东时间
9.585
-0.475
-4.72%
華盛通- 最 高10.17
- 今 開10.17
- 成交量 8522股
- 最 低 9.50
- 昨 收 10.06
- 總市值 1866.18万
- 52周最高 44.20
- 市盈率 靜 --
- 換手率 0.44%
- 52周最低 3.015
- 委 比 67.95%
- 總股本 194.70万
- 歷史最高 95200.00
- 量 比 0.54
- 振 幅 6.66%
- 歷史最低 4.804
- 每 手 1
- 風險率 9.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Akari Therapeutics participated in the Virtual Investor "Why Now" on-demand conference, where CEO Abizer Gaslightwala discussed the company's investment potential, focusing on its innovative ADC platform with RNA splicing modulator payloads. Akari's PH1 payload addresses limitations of traditional ADCs and targets key oncogenic drivers. The company is advancing AKTX-101 and AKTX-102, with plans for Phase I trials by mid-2027. The webcast is avail...
08-27 13:01
Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy
Akari Therapeutics Plc (NASDAQ:AKTX) on Tuesday shared promising preclinical results for its experimental cancer treatment, AKTX-101. The data highlights the therapy’s potential as a unique option for urothelial cancer, particularly in scenarios where currently available antibody-drug conjugates (AD...
08-18 23:37
Akari Therapeutics Says Strategic Research Collaboration With Whitehawk Therapeutics Expands Potential Application Of Akari’s PH1 Platform Into Dual-Payload ADCs
Expanded the Company's strategic position in novel ADC payloads through a research collaboration on dual ADC payloads with Whitehawk Therapeutics to evaluate Akari's proprietary PH1 spliceosome modulating payload platform in combination with Whitehawk's topoisomerase I payload platform. The collabor...
08-14 04:45
Why Amazon Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Shares of Amazon.com Inc (NASDAQ:AMZN) rose sharply in pre-market trading after the company posted upbeat financial results for the second quarter. Amazon reported second-quarter revenue of $200.61 billion, beating the consensus estimate of $196.46 billion, according to Benzinga Pro. The company pos...
07-31 16:50
美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
Akari Therapeutics and Whitehawk Therapeutics have entered into a strategic research collaboration to evaluate Akari's PH1 spliceosome-modulating payload technology in combination with Whitehawk's TOP1i ADC platform. The collaboration aims to explore dual payload compatibility and synergies, with Akari leading the research activities. Both companies will review interim data and assess potential broader development opportunities. This partnership ...
07-21 11:05
Maxim Group Upgrades Akari Therapeutics to Buy, Announces $30 Price Target
Maxim Group analyst Jason McCarthy upgrades Akari Therapeutics (NASDAQ:AKTX) from Hold to Buy and announces $30 price target.
07-21 02:15
Akari Therapeutics shareholders approve key AGM resolutions
Akari Therapeutics ( ($AKTX) ) has provided an announcement. On June 30, 2026, ...
07-03 05:50
Akari Therapeutics Files Prospectus Related To Resale Of Up To 6M ADSs Representing 480B Ordinary Shares By The Selling Shareholders
Akari Therapeutics Files Prospectus Related To Resale Of Up To 6M ADSs Representing 480B Ordinary Shares By The Selling Shareholders
07-03 05:30
Akari Therapeutics Streamlines Private Placement Financing Tranches
An update from Akari Therapeutics ( ($AKTX) ) is now available. On May 22, 2026...
06-27 05:52
